{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:51:23Z","timestamp":1791582683877,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008439","name":"Texas Christian University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bvth.2026.100141","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:49:24Z","timestamp":1768931364000},"page":"100141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A contemporary review of plasminogen activator inhibitor 1 in cardiovascular disease and broader disease state implications"],"prefix":"10.1016","volume":"3","author":[{"given":"Mebeli","family":"Becerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Soogoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4487-8112","authenticated-orcid":false,"given":"Jacob","family":"Wortley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-9264","authenticated-orcid":false,"given":"Mohanakrishnan","family":"Sathyamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bvth.2026.100141_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.0000023186.60090.FB","article-title":"Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1","volume":"106","author":"Eren","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.bvth.2026.100141_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.thromres.2008.07.004","article-title":"Transgenic overexpression of a stable plasminogen activator inhibitor-1 variant","volume":"123","author":"Fahim","year":"2009","journal-title":"Thromb Res"},{"issue":"25","key":"10.1016\/j.bvth.2026.100141_bib3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198512193132501","article-title":"Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction","volume":"313","author":"Hamsten","year":"1985","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/gtmb.2009.0039","article-title":"Association of PAI-1 4G\/5G and -844G\/A gene polymorphisms and changes in PAI-1\/tissue plasminogen activator levels in myocardial infarction: a case-control study","volume":"14","author":"Abboud","year":"2010","journal-title":"Genet Test Mol Biomarkers"},{"issue":"3","key":"10.1016\/j.bvth.2026.100141_bib5","first-page":"266","article-title":"Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction","volume":"114","author":"Fu","year":"2001","journal-title":"Chin Med J"},{"issue":"4","key":"10.1016\/j.bvth.2026.100141_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1134\/S0026893320040123","article-title":"[Age-dependent approach to search for genetic variants associated with myocardial infarction]","volume":"54","author":"Osmak","year":"2020","journal-title":"Mol Biol (Mosk)"},{"issue":"8","key":"10.1016\/j.bvth.2026.100141_bib7","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/01.STR.0000174485.10277.24","article-title":"Plasminogen activator inhibitor-1 4G\/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts","volume":"36","author":"Wiklund","year":"2005","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib8","first-page":"2097","article-title":"PAI-1 4G\/5G polymorphism and coronary artery disease risk: a meta-analysis","volume":"8","author":"Liang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13018-018-0716-2","article-title":"Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty","volume":"13","author":"Tang","year":"2018","journal-title":"J Orthop Surg Res"},{"issue":"12","key":"10.1016\/j.bvth.2026.100141_bib10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/clc.23282","article-title":"Genetic association between plasminogen activator inhibitor-1 rs1799889 polymorphism and venous thromboembolism: evidence from a comprehensive meta-analysis","volume":"42","author":"Huang","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.bvth.2026.100141_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.gene.2018.06.040","article-title":"The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: a systematic review and meta-analysis involving 149,908 subjects","volume":"673","author":"Liu","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.bvth.2026.100141_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.622473","article-title":"Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition","volume":"7","author":"Sillen","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.CIR.79.1.101","article-title":"Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)","volume":"79","author":"Angleton","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.bvth.2026.100141_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb J"},{"issue":"13","key":"10.1016\/j.bvth.2026.100141_bib15","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V96.13.4212","article-title":"Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery","volume":"96","author":"Eitzman","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bvth.2026.100141_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/hq0302.104529","article-title":"Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice","volume":"22","author":"Luttun","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"10.1016\/j.bvth.2026.100141_bib17","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1073\/pnas.89.15.6998","article-title":"Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries","volume":"89","author":"Schneiderman","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0008-6363(97)00144-2","article-title":"Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants","volume":"36","author":"Padr\u00f3","year":"1997","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0038-1648809","article-title":"Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls","volume":"72","author":"Chomiki","year":"1994","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.bvth.2026.100141_bib20","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/ATVBAHA.116.308344","article-title":"Pharmacological targeting of plasminogen activator inhibitor-1 decreases vascular smooth muscle cell migration and neointima formation","volume":"36","author":"Ji","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.bvth.2026.100141_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11239-007-0083-z","article-title":"Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease","volume":"26","author":"Onalan","year":"2008","journal-title":"J Thromb Thrombolysis"},{"issue":"3-4","key":"10.1016\/j.bvth.2026.100141_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0049-3848(02)00254-2","article-title":"The 4G\/5G-polymorphism in the PAI-1 gene is not associated with markers of atherosclerosis in male smokers","volume":"107","author":"Hoekstra","year":"2002","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.bvth.2026.100141_bib23","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms22052721","article-title":"A narrative review on plasminogen activator inhibitor-1 and its (patho)physiological role: to target or not to target?","volume":"22","author":"Sillen","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.bvth.2026.100141_bib24","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/01.CIR.94.9.2057","article-title":"Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European concerted action on thrombosis and disabilities","volume":"94","author":"Juhan-Vague","year":"1996","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.STR.31.1.26","article-title":"Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator\/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke","volume":"31","author":"Johansson","year":"2000","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.bvth.2026.100141_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0895-4356(03)00052-0","article-title":"Prospective study of fibrinolytic markers and venous thromboembolism","volume":"56","author":"Folsom","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.bvth.2026.100141_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb J"},{"issue":"10","key":"10.1016\/j.bvth.2026.100141_bib28","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.3390\/ijms23105516","article-title":"PAI-1: a major player in the vascular dysfunction in obstructive sleep apnea?","volume":"23","author":"Badran","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.bvth.2026.100141_bib29","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/cells12101402","article-title":"PAI-1 overexpression in valvular interstitial cells contributes to hypofibrinolysis in aortic stenosis","volume":"12","author":"Kopytek","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41598-020-79948-x","article-title":"Role of PAI-1 in hepatic steatosis and dyslipidemia","volume":"11","author":"Levine","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1538-7836.2003.00533.x","article-title":"Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1)","volume":"2","author":"Lijnen","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.bvth.2026.100141_bib32","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1161\/01.CIR.96.9.3180","article-title":"Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice","volume":"96","author":"Carmeliet","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.bvth.2026.100141_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.02.135","article-title":"Role of plasminogen activator inhibitor-1 in coronary pathophysiology","volume":"164","author":"Jung","year":"2018","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.bvth.2026.100141_bib34","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/jth.14160","article-title":"Hemorrhagic disorders of fibrinolysis: a clinical review","volume":"16","author":"Saes","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.bvth.2026.100141_bib35","series-title":"Platelet","year":"2024"},{"key":"10.1016\/j.bvth.2026.100141_bib36","series-title":"Blood Vessel","year":"2024"},{"key":"10.1016\/j.bvth.2026.100141_bib37","series-title":"Red Blood Cell","year":"2024"},{"issue":"5","key":"10.1016\/j.bvth.2026.100141_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/jpm14050537","article-title":"Interactions and trends of interleukins, PAI-1, CRP, and TNF-\u03b1 in inflammatory responses during the perioperative period of joint arthroplasty: implications for pain management\u2014a narrative review","volume":"14","author":"Cocea","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.bvth.2026.100141_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1445294","article-title":"The influence of 4G\/5G polymorphism in the plasminogen-activator-inhibitor-1 promoter on COVID-19 severity and endothelial dysfunction","volume":"15","author":"Yatsenko","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bvth.2026.100141_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2022.100110","article-title":"The mechanistic basis linking cytokine storm to thrombosis in COVID-19","volume":"8","author":"Wolf","year":"2022","journal-title":"Thromb Update"},{"key":"10.1016\/j.bvth.2026.100141_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib42","doi-asserted-by":"crossref","first-page":"C209","DOI":"10.1152\/ajpcell.00157.2006","article-title":"IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C\/EBP\u03b4","volume":"292","author":"Dong","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"issue":"23","key":"10.1016\/j.bvth.2026.100141_bib43","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.3390\/ijms232314914","article-title":"The role of the coagulation system in peripheral arterial disease: interactions with the arterial wall and its vascular microenvironment and implications for rational therapies","volume":"23","author":"Miceli","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.bvth.2026.100141_bib44","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1152\/japplphysiol.01220.2004","article-title":"TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue","volume":"98","author":"Plomgaard","year":"2005","journal-title":"J Appl Physiol (1985)"},{"issue":"22","key":"10.1016\/j.bvth.2026.100141_bib45","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1111\/j.1742-4658.2005.04979.x","article-title":"Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G\/5G site","volume":"272","author":"Swiatkowska","year":"2005","journal-title":"FEBS J"},{"key":"10.1016\/j.bvth.2026.100141_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2022.100110","article-title":"The mechanistic basis linking cytokine storm to thrombosis in COVID-19","volume":"8","author":"Wolf","year":"2022","journal-title":"Thromb Update"},{"key":"10.1016\/j.bvth.2026.100141_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1390698","article-title":"Corrigendum: urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19","volume":"15","author":"Yatsenko","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bvth.2026.100141_bib46","series-title":"Arteriole Cross Section","year":"2024"},{"key":"10.1016\/j.bvth.2026.100141_bib47","series-title":"Macrophage","year":"2024"},{"issue":"6","key":"10.1016\/j.bvth.2026.100141_bib50","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.3390\/ijms22063170","article-title":"PAI-1 in diabetes: pathophysiology and role as a therapeutic target","volume":"22","author":"Altalhi","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.bvth.2026.100141_bib51","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s11255-016-1333-9","article-title":"Association between PAI-1 4G\/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population","volume":"48","author":"Gao","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"10.1016\/j.bvth.2026.100141_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144557","article-title":"Role of ACE and PAI-1 polymorphisms in the development and progression of diabetic retinopathy","volume":"10","author":"Saleem","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib53","doi-asserted-by":"crossref","first-page":"E260","DOI":"10.1152\/ajpendo.00387.2018","article-title":"Inhibition of PAI-1 attenuates perirenal fat inflammation and the associated nephropathy in high-fat diet-induced obese mice","volume":"316","author":"Liu","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.bvth.2026.100141_bib54","first-page":"201","article-title":"Thrombotic risk assessed by PAI-1 in patients with COVID-19: the influence of hyperglycemia and diabetes mellitus","volume":"36","author":"Basurto","year":"2024","journal-title":"Clin Investig Arterioscler"},{"issue":"43","key":"10.1016\/j.bvth.2026.100141_bib55","doi-asserted-by":"crossref","first-page":"32796","DOI":"10.1074\/jbc.M606214200","article-title":"Bone marrow plasminogen activator inhibitor-1 influences the development of obesity","volume":"281","author":"De Taeye","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.bvth.2026.100141_bib56","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/oby.23112","article-title":"Inhibition of PAI-1 promotes lipolysis and enhances weight loss in obese mice","volume":"29","author":"Levine","year":"2021","journal-title":"Obesity"},{"issue":"6","key":"10.1016\/j.bvth.2026.100141_bib57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1113\/expphysiol.2005.030718","article-title":"Human gender differences in fibrinolytic responses to exercise training and their determinants","volume":"90","author":"Kulaputana","year":"2005","journal-title":"Exp Physiol"},{"key":"10.1016\/j.bvth.2026.100141_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2024.107071","article-title":"Increased plasminogen activator inhibitor-1 (PAI-1) and its associations with metabolic risk in healthy young adults with early life stress","volume":"166","author":"Kudinova","year":"2024","journal-title":"Psychoneuroendocrinology"},{"issue":"3","key":"10.1016\/j.bvth.2026.100141_bib59","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MOL.0b013e32814e6d29","article-title":"Plasminogen activator inhibitor-1, adipose tissue and insulin resistance","volume":"18","author":"Alessi","year":"2007","journal-title":"Curr Opin Lipidol"},{"issue":"50","key":"10.1016\/j.bvth.2026.100141_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023660","article-title":"Association between plasminogen activator inhibitor-1 (PAI-1) 4G\/5G polymorphism and risk of alzheimer's disease, metabolic syndrome, and female infertility: a meta-analysis","volume":"99","author":"Zhang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"19","key":"10.1016\/j.bvth.2026.100141_bib61","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.3390\/ijms21197066","article-title":"PAI-1, the plasminogen system, and skeletal muscle","volume":"21","author":"Rahman","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2025.114677","article-title":"PAI-1 regulates extracellular matrix remodeling and alters fibroblast profibrotic ability in skeletal muscle repair","volume":"450","author":"Li","year":"2025","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1152\/ajpcell.00555.2004","article-title":"Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration","volume":"289","author":"Koh","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"10.1016\/j.bvth.2026.100141_bib64","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/db11-0007","article-title":"Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice","volume":"60","author":"Krause","year":"2011","journal-title":"Diabetes"},{"issue":"13","key":"10.1016\/j.bvth.2026.100141_bib65","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.3390\/ijms21134575","article-title":"Impaired ECM remodeling and macrophage activity define necrosis and regeneration following damage in aged skeletal muscle","volume":"21","author":"Rahman","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bvth.2026.100141_bib66","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.bbrc.2020.10.089","article-title":"A novel PAI-1 inhibitor prevents ageing-related muscle fiber atrophy","volume":"534","author":"Aihemaiti","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.bvth.2026.100141_bib67","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3390\/biomedicines10102665","article-title":"Genetic markers for thrombophilia and cardiovascular disease associated with multiple sclerosis","volume":"10","author":"Hadjiagapiou","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bvth.2026.100141_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/362708","article-title":"The role of TPA I\/D and PAI-1 4G\/5G polymorphisms in multiple sclerosis","volume":"2014","author":"Zivkovi\u0107","year":"2014","journal-title":"Dis Markers"},{"issue":"39","key":"10.1016\/j.bvth.2026.100141_bib69","doi-asserted-by":"crossref","first-page":"36025","DOI":"10.1021\/acsomega.3c04076","article-title":"Serum PAI-1\/BDNF ratio is increased in Alzheimer's disease and correlates with disease severity","volume":"8","author":"Angelucci","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bvth.2026.100141_bib70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/bs.vh.2016.10.004","article-title":"BDNF and hippocampal synaptic plasticity","volume":"104","author":"Leal","year":"2017","journal-title":"Vitam Horm"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib71","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4172\/2324-8769.1000106","article-title":"Novel combinatorial therapeutic targeting of PAI-1 (SERPINE1) gene expression in Alzheimer's disease","volume":"1","author":"Kutz","year":"2012","journal-title":"Mol Med Ther"},{"issue":"25","key":"10.1016\/j.bvth.2026.100141_bib72","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1073\/pnas.0710823105","article-title":"Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade","volume":"105","author":"Jacobsen","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib73","first-page":"515","article-title":"Aging, plasminogen activator inhibitor 1, brain cell senescence, and Alzheimer's disease","volume":"14","author":"Jiang","year":"2023","journal-title":"Aging Dis"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3233\/JAD-180241","article-title":"A small molecule inhibitor of plasminogen activator inhibitor-1 reduces brain amyloid-\u03b2 load and improves memory in an animal model of Alzheimer\u2019s disease","volume":"64","author":"Akhter","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.bvth.2026.100141_bib75","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s00213-023-06459-8","article-title":"Pharmacological inhibition of plasminogen activator inhibitor-1 prevents memory deficits and reduces neuropathology in APP\/PS1 mice","volume":"240","author":"Rodriguez","year":"2023","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.bvth.2026.100141_bib76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3816\/CBC.2004.n.040","article-title":"Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer","volume":"5","author":"Harbeck","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.bvth.2026.100141_bib77","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/jcp.21806","article-title":"Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism","volume":"220","author":"Czekay","year":"2009","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.bvth.2026.100141_bib78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0065-2423(07)00002-9","article-title":"uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial","volume":"45","author":"Annecke","year":"2008","journal-title":"Adv Clin Chem"},{"issue":"3","key":"10.1016\/j.bvth.2026.100141_bib79","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-2007-1002624","article-title":"Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer","volume":"17","author":"J\u00e4nicke","year":"1991","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib80","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.imlet.2008.03.017","article-title":"The plasminogen activator inhibitor \u201cparadox\u201d in cancer","volume":"118","author":"Binder","year":"2008","journal-title":"Immunol Lett"},{"issue":"6","key":"10.1016\/j.bvth.2026.100141_bib81","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/erm.11.47","article-title":"Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1","volume":"11","author":"Schmitt","year":"2011","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"10.1016\/j.bvth.2026.100141_bib82","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1200\/JCO.1994.12.8.1648","article-title":"Plasminogen activator inhibitor-1 and prognosis in primary breast cancer","volume":"12","author":"Foekens","year":"1994","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bvth.2026.100141_bib83","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-0033-1338127","article-title":"The apparent uPA\/PAI-1 paradox in cancer: more than meets the eye","volume":"39","author":"Kwaan","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"10.1016\/j.bvth.2026.100141_bib84","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jnci\/87.10.751","article-title":"Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer","volume":"87","author":"Foekens","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.bvth.2026.100141_bib85","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10555-019-09806-4","article-title":"The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding","volume":"38","author":"Kubala","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.bvth.2026.100141_bib86","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biopha.2018.05.119","article-title":"Plasminogen activator inhibitor-1 in cancer research","volume":"105","author":"Li","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"15","key":"10.1016\/j.bvth.2026.100141_bib87","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-15-0876","article-title":"Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing","volume":"75","author":"Placencio","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.bvth.2026.100141_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216117","article-title":"Good or bad: paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.bvth.2026.100141_bib89","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.celrep.2018.10.082","article-title":"Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer","volume":"25","author":"Kubala","year":"2018","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.bvth.2026.100141_bib90","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1055\/s-0038-1675399","article-title":"The urokinase plasminogen activator system in human cancers: an overview of its prognostic and predictive role","volume":"118","author":"Maduni\u0107","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/ijms23010337","article-title":"The plasminogen-activator plasmin system in physiological and pathophysiological angiogenesis","volume":"23","author":"Ismail","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bvth.2026.100141_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1365894","article-title":"Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1","volume":"15","author":"Ibrahim","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.bvth.2026.100141_bib93","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","article-title":"Coagulation and sepsis","volume":"149","author":"Levi","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.bvth.2026.100141_bib94","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fcvm.2017.00062","article-title":"Getting old through the blood: circulating molecules in aging and senescence of cardiovascular regenerative cells","volume":"4","author":"Angelini","year":"2017","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"10.1016\/j.bvth.2026.100141_bib95","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1055\/s-0034-1387883","article-title":"Role of plasminogen activator inhibitor-1 in senescence and aging","volume":"40","author":"Eren","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1016\/j.bvth.2026.100141_bib96","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1755-5922.2010.00171.x","article-title":"Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions","volume":"28","author":"Cesari","year":"2010","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.bvth.2026.100141_bib97","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.celrep.2013.03.028","article-title":"p21 both attenuates and drives senescence and aging in BubR1 progeroid mice","volume":"3","author":"Baker","year":"2013","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.bvth.2026.100141_bib98","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/ATVBAHA.117.309451","article-title":"Plasminogen activator inhibitor-1 is a marker and a mediator of senescence","volume":"37","author":"Vaughan","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.bvth.2026.100141_bib99","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cardiores.2004.11.013","article-title":"Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly","volume":"66","author":"Yamamoto","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.bvth.2026.100141_bib100","article-title":"PAI-1 as a critical factor in the resolution of sepsis and acute kidney injury in old age","volume":"11","author":"Bruno","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.bvth.2026.100141_bib101","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2006-05-025197","article-title":"Plasminogen activator inhibitor type 1 is protective during severe gram-negative pneumonia","volume":"109","author":"Renckens","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bvth.2026.100141_bib102","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/thx.2010.155788","article-title":"PAI-1 is an essential component of the pulmonary host response during pseudomonas aeruginosa pneumonia in mice","volume":"66","author":"Goolaerts","year":"2011","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.bvth.2026.100141_bib103","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1213\/ANE.0000000000005147","article-title":"COVID-19-associated coagulopathy and inflammatory response: what do we know already and what are the knowledge gaps?","volume":"131","author":"G\u00f6rlinger","year":"2020","journal-title":"Anesth Analg"},{"issue":"6","key":"10.1016\/j.bvth.2026.100141_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282939","article-title":"Integral assays of hemostasis in hospitalized patients with COVID-19 on admission and during heparin thromboprophylaxis","volume":"18","author":"Bulanov","year":"2023","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bvth.2026.100141_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243604","article-title":"Coagulation profile of COVID-19 patients admitted to the ICU: an exploratory study","volume":"15","author":"Corr\u00eaa","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bvth.2026.100141_bib106","doi-asserted-by":"crossref","first-page":"16290","DOI":"10.1038\/s41598-021-95397-6","article-title":"Altered platelet and coagulation function in moderate-to-severe COVID-19","volume":"11","author":"Litvinov","year":"2021","journal-title":"Sci Rep"}],"updated-by":[{"DOI":"10.1016\/j.bvth.2026.100211","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:02:55Z","timestamp":1791579775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950327226000069"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100141","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A contemporary review of plasminogen activator inhibitor 1 in cardiovascular disease and broader disease state implications","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100141"}}